GEFITINIB

Gefitinib is an EGFR tyrosine kinase inhibitor used in nonsmallcell lung cancer. Side effects include rash, diarrhea, and liver enzyme elevation. Only GMP materials will be supplied, logistics all according to GDP.

SKU: a61a4acc27e1 Category: Tag:

Product Description


Mechanism of Action

Gefitinib is a selective EGFR tyrosine-kinase inhibitor that blocks ATP binding to the intracellular kinase domain, inhibiting signalling pathways involved in tumor growth, proliferation and survival.

Benefits and Advantages

Used in EGFR-signalling research, oncogenic mutation modelling, kinase-inhibition assays and cancer therapeutics screening.

Side Effects and Risks

Rash, diarrhea, hepatotoxicity and interstitial lung disease. Handle with cytotoxic-kinase inhibitor precautions.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C22H24ClFN4O3

Molecular Weight

446.9 g/mol

CAS Number

184475-35-2

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Sparingly soluble (<pH4)

Purity

Purity information is available upon request (COA).

Synonym

Gefitinib; 184475-35-2; Iressa; ZD1839; Irressat

IUPAC/Chemical Name

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine

InChl Key

XGALLCVXEZPNRQ-UHFFFAOYSA-N

InChl Code

InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

References

https://pubchem.ncbi.nlm.nih.gov/compound/123631;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download